Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320112 | 0.84 | EPHX1 (0.85) | EPHX1MMP2MMP1ACHE | |
| SCHEMBL30786047 | 0.82 | EPHX1 (0.90) | EPHX1EPHX2MMP2MMP1ACHE | |
| SCHEMBL11571691 | 0.82 | CA12 (0.39) | EPHX1 | |
| SCHEMBL28215302 | 0.81 | EPHX1 (0.65) | EPHX1EPHX2POLBMMP2MMP1 | |
| SCHEMBL14064986 | 0.80 | CASP2 (0.55) | EPHX1EPHX2 | |
| SCHEMBL22068239 | 0.80 | PAOX (0.52) | EPHX1EPHX2 | |
| SCHEMBL17133784 | 0.80 | EPHX1 (0.95) | EPHX1EPHX2 | |
| SCHEMBL9323761 | 0.80 | EPHX1 (0.82) | EPHX1EPHX2MMP2MMP1ACHE | |
| SCHEMBL28407900 | 0.79 | EPHX1 (0.63) | EPHX1EPHX2POLBMMP2MMP1 | |
| SCHEMBL28413519 | 0.79 | EPHX1 (0.57) | EPHX1EPHX2CYP2C9MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | HTRA1, ALDH1A2, PREP | EPHX1 2154/4885EPHX2 3811/4885CYP2C9 2820/4885 |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, PREP | EPHX1 2154/4885EPHX2 3811/4885CYP2C9 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.